Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed results and management update for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 operating expenses $54.8M, up from $44.9M, reflecting heavier clinical development spending
- Net loss $50.4M, or $0.15 per share, versus $41.4M, or $0.19 per share, in Q3 2025
- Cash, equivalents and investments $388.9M at September 30, supporting projected runway into 2029
- ALPHA3 enrollment momentum continues, with next cema-cel update expected mid-2027 and enrollment completion by year-end 2027
- ALLO-329 autoimmune data update due November 9, expanding results beyond the published nine-patient dataset
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.